MK-677 vs Thymosin Beta-4
Well Studied vs Well Studied
synergistic Mechanism-based · 47% MK-677 and Thymosin Beta-4 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
MK-677 Thymosin Beta-4
Weight 624.77 Da 4,963.44 Da
Half-life ~24 hours Dose-dependent; relatively short (exact values not established)
Chain — 43 amino acids
Type Non-peptide ghrelin receptor agonist Thymosin peptide
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
MK-677 Thymosin Beta-4
Status Well Studied Well Studied
References 7 studies 4 studies
Latest July 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.